ArticleACS catalysis2026
Photoredox-Neutral Platform for Direct Decarboxylative Cyclopropanation
Article in ACS catalysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
A photoredox-neutral approach to cyclopropanes from in situ generated non-stabilized carbenes via a new acridine-iron dual catalytic system is reported. This strategy merges the oxidative decarboxylation of bench-stable carboxylic acids with the reduction of an iron porphyrin under mild photochemical conditions. Bespoke acridine photocatalysts efficiently shuttle electrons between carboxylic acids and iron complexes, obviating the need for a sacrificial reductant. Mechanistic studies reveal that, contrary to prevailing assumptions, decarboxylation does not proceed through a concerted PCET pathway but instead via a stepwise proton transfer followed by a highly exergonic electron transfer and decarboxylation event. Density functional theory calculations further support the formation of a key Fe(IV)-carbenoid intermediate, which engages alkenes through a stepwise, radical-type carbene transfer mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.